Esperion Therapeutics
ESPR
$1.90
Share price
-4.52%
Change (1 day)
57.02%
Change (1 year)
Categories
Esperion Therapeutics (ESPR) - P/B ratio
P/B ratio as of April 2024 : -0.7910
According to Esperion Therapeutics's latest financial reports the company has a price-to-book ratio of -0.7910.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Esperion Therapeutics - P/B ratio (from 2013 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | -0.7473 | -47.29% |
| 2022-12-31 | -1.42 | -8.3% |
| 2021-12-31 | -1.55 | -77.94% |
| 2020-12-31 | -7.01 | -108.53% |
| 2019-12-31 | 82.2 | 426.99% |
| 2018-12-31 | 15.6 | 121.25% |
| 2017-12-31 | 7.05 | 470.68% |
| 2016-12-31 | 1.24 | -29.21% |
| 2015-12-31 | 1.74 | -71.67% |
| 2014-12-31 | 6.16 | 116.53% |
| 2013-12-31 | 2.84 | |
| 2012-12-31 | N/A | |
| 2003-12-31 | N/A | |
| 2002-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.61 | -303.58% | 🇺🇸 USA |
 Regeneron Pharmaceuticals REGN | 3.73 | -572.10% | 🇺🇸 USA |
 Ultragenyx RARE | 13.2 | -1,771.73% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | 2.79 | -452.58% | 🇺🇸 USA |
 Amicus Therapeutics
FOLD | 19.0 | -2,504.42% | 🇺🇸 USA |
 BioMarin Pharmaceutical BMRN | 3.11 | -492.62% | 🇺🇸 USA |